Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Choosing an oral form to "avoid injection risks" does not eliminate the underlying uncertainty about the compound itself or about product quality
After 3 h of OGD treatment in HUVECs, WB results showed that the expression of Ki-67 and Lamin B decreased, while the expression of P53, P21, P16, and -H2AX significantly increased (Figure 3A)
The dose may be increased at 4- to 8-week intervals according to individual patient requirements to a maximum of 0.08 mg/kg/week, depending upon patient tolerance of treatment
*Claims of personalization and potential reduction in side effects are based on the ability of compounding to customize treatment for individual needs
